

TARGET AUDIENCE

This educational program is designed to be of high clinical utility to medical, surgical and radiation oncologists practicing in the community or academic institutions. Oncology fellows, oncology nurses, oncology physician assistants, scientists and pharmacists interested in the treatment of breast cancer are also invited to attend.

SUPPORT HAS BEEN REQUESTED FROM

ASCO
American Society of Clinical Oncology

CAMERA DI COMMERCIO DI CREMONA
CROCE ROSSA ITALIANA
ORDINE DEI MEDICI DI CREMONA
SOCIETÀ ITALIANA DI SENOLOGIA

SUPPORTED BY



The meeting is accredited with
10 ESMO-MORA points Category 1

ORGANIZING SECRETARIAT

Over Media Consult Srl
Via Manini 31 - 26100 Cremona
Phone +39 0372 23310 Fax +39 0372 569605
www.overconsult.it
info@overconsult.it

For any further information please visit the website
www.bu-cremona.org

SCIENTIFIC BOARD

M. Aglietta (Candiolo, Turin, IT)
E. De Azambuja (Bruxelles, BE)
F. Bertolini (Milan, IT)
A. Berruti (Orbassano, Turin, IT)
A. Bottini (Cremona, IT)
P. Bruzzi (Genoa, IT)
P.F. Conte (Modena, IT)
G. Curigliano (Milan, IT)
M. Daidone (Milan, IT)
G. Damia (Milan, IT)
M. Danova (Pavia, IT)
S. Di Cosimo (Barcelona, ES)
L. Dogliotti (Orbassano, Turin, IT)
G. Dontu (London, UK)
M. Dowsett (London, UK)
P. Fenaroli (Bergamo, IT)
F. Ferrozzi (Parma, IT)
S.B. Fox (Melbourne, AUS)
M. Garassino (Milan, IT)
D. Generali (Cremona, IT)
A. Gennari (Genova, IT)
L. Gianni (Milan, IT)
M. Greco (Milan, IT)
A.L. Harris (Oxford, UK)
M. Kaufmann (Frankfurt, DE)
D. Kennedy (Brisbane, AUS)
A. Makris (Northwood, UK)
R. Mansel (Cardiff, UK)
S. Marsoni (Milan, IT)
W. R. Miller (Edinburgh, UK)
L. Olivetti (Cremona, IT)
P.G. Petronini (Parma, IT)
L. Pusztai (Houston, USA)
A. Sapino (Turin, IT)
C. Sotiriou (Bruxelles, BE)
E. Tagliabue (Milan, IT)
C. Tondini (Bergamo, IT)
V. Torri (Milan, IT)
G.P. Tortora (Naples, IT)
M. Untch (Berlin, DE)
L. Van't Veer (Amsterdam, NL)
M. Venturini (Verona, IT)
G. Von Minckwitz (Frankfurt, DE)

Fourth
International Symposium
The Consensus Conference

PRIMARY SYSTEMIC TREATMENT IN THE MANAGEMENT OF OPERABLE BREAST CANCER

Toward the rapid assessment of therapy efficacy

CREMONA (Italy)

26th - 28th September 2010



Abitanti Felice - Ragazza che pettina l'amica - 80x100

Azienda Ospedaliera
Istituti Ospitalieri di Cremona

Azienda Ospedaliero-Universitaria
San Luigi Gonzaga Orbassano TO

Dipartimento Provinciale
di Oncologia

Università degli Studi
di Torino

Dipartimento Provinciale
di Chirurgia

Dipartimento di Scienze
Cliniche e Biologiche

Unità di Patologia Mammaria
Breast Unit

Oncologia Medica

SYMPOSIUM LOCATION

Palazzo Cittanova - C.so Garibaldi, 135 - CREMONA (Italy)

Primary Systemic anti-neoplastic treatment is increasingly adopted either in clinical trials or daily practice as treatment for both operable and locally advanced breast cancers.

This treatment approach represents an ideal setting to test the tumour sensitivity in vivo to a selected therapeutic approach; it also allows the explanation of the interaction between anti-neoplastic therapy and tumour biology, and can provide surrogate parameters of treatment efficacy.

The Unità di Patologia Mammaria - Breast Cancer Unit located within the Azienda "Istituti Ospitalieri di Cremona" has team up with leaders in the field to organise the Fourth International Symposium to highlight and discuss the state of the art and future directions in primary systemic treatment of operable breast cancer.

Sunday, 26th September 2010

Afternoon Session:

- 14:00** Registration
- 14:30** Official Welcome from Breast Unit Leaders
A. BOTTINI, P. FENAROLI, R. MANSEL
- 15:00** Up-date from Frankfurt-Biedenkopf Round-Table
M. KAUFMANN, G. VON MINCKWITZ
- 16:00** Introductory Lecture
L. VAN'T VEER
- 17:00** Opening Ceremony and Welcome Party

Monday, 27th September 2010

Morning Session:
The round-trip: bench-bedside-bench
G. DAMIA, D. KENNEDY, P. G. PETRONINI

- 9:30** Translation strategies to turn in vitro information to clinical benefits
M. DAIDONE
- 10:00** Pharmacogenomics to guide successful development of old and new therapies
L. PUSZTAI

- 10:30** Biomarkers predicting clinical benefits: Fact or Fiction?
G. TORTORA
- 11:00** Breast Cancer Stem cells: role and clinical potentiality
G. DONTU
- 11:30** Discussion: Outlines for the Statement on Primary Chemotherapy
G. DAMIA, D. KENNEDY, P. G. PETRONINI
- 12:00** Lunch Session:
Step to the Future, the EYO

ESMO Young Oncologists Classroom:
Perspective of Primary Chemotherapy in Breast Cancer
Interactive Poster and Abstract Discussion
S. DI COSIMO, M. GARASSINO
- Afternoon Session: Treatment interaction with tumour biology,
Lost in Translation
M. AGLIETTA, F. BERTOLINI, S. FOX
- 14:00** Metabolic and molecular response for treatment responsiveness/resistance
D. GENERALI
- 14:30** Mechanism of resistance to target-therapy based-combinations
P. CONTE
- 15:00** Mechanism of resistance to anti-angiogenic therapy
A. L. HARRIS
- 15:30** Tissue and soluble biomarkers and their applications: ready to use!
M. DANOVA
- 16:00** The triple-negative subtype: new ideas for the poorest-prognosis breast cancer
G. CURIGLIANO
- 16:30** The HER2 world: the better agents selection for the better outcome
E. TAGLIABUE
- 17:00** Discussion: Outlines for the Statement on Primary Chemotherapy
M. AGLIETTA, F. BERTOLINI, S. FOX

Tuesday, 28th September 2010

Morning Session: State of the art and perspectives
A. GENNARI, L. OLIVETTI, C. TONDINI

- 09:00** The surgeon's role in the neo-adjuvant treatment with target-therapies
M. GRECO
Trouble-shooting for pathologist
- 09:20** The pCR open-question in primary therapy
A. SAPINO

- 09:40** Surrogate markers for target-therapy based-treatment activity and efficacy
L. GIANNI
- 10:00** Clinical and pathological post-therapy assessment and prognosis
S. B. FOX
New radiological perspectives in neo-adjuvant setting
- 10:20** DCE-MRI and BOLD-MRI for tumour biology changes under treatment
A. MAKRIS
- 10:40** PET-CT role in primary therapy
F. FERROZZI
The new combinations for the breast cancer oncologist
- 11:00** Chemotherapy and biological drugs
E. DE AZAMBUJA
- 11:20** Endocrine-therapy and new biologicals
M. DOWSETT
- 11:40** Discussion: Outlines for the Statement on Primary Chemotherapy
A. GENNARI, L. OLIVETTI, C. TONDINI
- 12:10** Lunch Session: EYO - interactive discussion with biotechnology industry involved in oncology drug discovery
S. DI COSIMO, M. GARASSINO
- 13:40** Afternoon Session: New approaches for clinical studies
P. BRUZZI, L. PUSZTAI, M. VENTURINI
- 14:00** New "Omics" information for clinical trial utility in the primary setting
S. MARSONI
- 14:30** Biometrics and bioinformatics: design a clinical trial with old and new agents
V. TORRI
- 15:00** Gene-profile assay and application: the predictive role in primary therapy
C. SOTIRIOU
- 15:30** Bridging the gap between translational research and clinical application
W. R. MILLER
- 16:00** Early Response as a guide for further treatment: clinical, radiological, biological
M. UNTCH
- 16:30** Waypoints and endpoints in primary therapy
A. BERRUTI
- 17:00** Discussion: Outlines for the Statement on Primary Chemotherapy
P. BRUZZI, L. PUSZTAI, M. VENTURINI